Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease DOI Creative Commons

Tatjána Ábel,

Béla Benczúr, Éva Csajbókné Csobod

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Sept. 23, 2024

Previously published studies have shown that women with type 2 diabetes a higher risk of atherosclerotic cardiovascular disease than men diabetes. The exact reason for this is not yet known. association between metabolic dysfunction-associated steatotic liver and appears to be bidirectional, meaning the onset one may increase progression other. Dyslipidemia common in both diseases. Our aim was therefore investigate whether there sex difference pathogenesis management dyslipidemia patients dysfunction. While majority date found no statin treatment, some reduced effectiveness compared men. Statin treatment under-prescribed diabetics disease. No differences were ezetimibe treatment. However, best our knowledge, such study fibrate Conflicting results on efficacy newer cholesterol-lowering PCSK9 inhibitors been reported Results from two real-world suggest up-titration dose improves women. Bempedoic acid has effective safe more lipid lowering men, based phase 3 date. Further research needed clarify plays role ASCVD

Language: Английский

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease DOI
Nobuharu Tamaki, Takefumi Kimura,

Shun‐ichi Wakabayashi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(8), P. 1033 - 1041

Published: Aug. 8, 2024

The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events major adverse cardiovascular (MACE).

Language: Английский

Citations

9
Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge DOI Open Access
Mohamad Jamalinia, Amedeo Lonardo

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(3)

Published: June 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum cardio-nephro-metabolic and vascular manifestations inherent in highlights complex profile CVD associated with this condition. However, current approaches to assessing lack specificity, predominantly relying on traditional markers. Although it widely accepted that patients advanced fibrosis are more prone risk, recent evidence suggests isolated focus may overlook remarkable phenotypic variability across entire population. Emerging data indicate a progressive escalation parallel severity MASLD, highlighting need precise staging inform accurate assessment. To address challenge, we propose novel sequential approach assessment MASLD. While factors remain essential, incorporating liver-specific parameters enhances stratification guides targeted interventions mitigate substantial burden vulnerable This involves initial screening using FIB-4 NAFLD score, followed by imaging-based non-invasive techniques individuals at intermediate-high fat quantification low-risk individuals. Future prospective investigations should simultaneous use biomarkers imaging modalities evaluate, sex-specific manner, efficacy proposed determine optimal thresholds steatosis

Language: Английский

Citations

5
Is liver fibrosis more advanced in MetALD than in MASLD? DOI
Hideki Fujii, Yoshihiro Kamada,

Akihiro Tokushige

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: July 1, 2024

Language: Английский

Citations

4
Steatotic Liver Disease: Navigating Pathologic Features, Diagnostic Challenges, and Emerging Insights DOI

Jingjing Jiao,

Xuchen Zhang

Advances in Anatomic Pathology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

Steatotic liver disease (SLD) is now used as an overarching category encompassing five subcategories: metabolic dysfunction-associated steatotic (MASLD), and alcohol related/associated (MetALD), alcohol-related/associated (ALD), SLD with specific etiology, cryptogenic SLD. This review summarizes foundational recent advances in the histologic evaluation of SLD, including common pathologic features across all subcategories, distinctions associated different etiologies, scoring grading systems, evolution digital pathology techniques for assessment.

Language: Английский

Citations

0
Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease DOI Creative Commons
Eda Kaya, Eduardo Vilar‐Gómez, Raj Vuppalanchi

et al.

Annals of Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 101907 - 101907

Published: March 1, 2025

Language: Английский

Citations

0
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality DOI
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Characterising the phenotypic features of individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) can help identify high-risk subpopulations within this group. High-sensitivity troponin (hs-troponin) is a significant risk factor for future cardiovascular events. We studied association hs-troponin in absence all-cause and cause-specific mortality among MASLD. used National Health Nutrition Examination Survey 1999-2004 linked dataset through 2019. Cox regression models to assess between MASLD without disease. During median follow-up period 17.5 years (IQR: 15.9-19.1), higher levels T were associated progressively hazards mortality, which remained after adjustment demographic, clinical, lifestyle factors. There was 29% (hazard ratio [HR]: 1.29, 95% confidence interval [CI]: 1.16-1.44) increase 44% (HR: 1.44, CI: 1.20-1.72) every rise 1-standard deviation T. A (p trend) noted 3 I assays, similar no cancer-related mortality. Screening or at-risk group that have predominantly due disease-related population

Language: Английский

Citations

0
AI‐Based Platelet‐Independent Noninvasive Test for Liver Fibrosis in MASLD Patients DOI Creative Commons

Shun‐ichi Wakabayashi,

Takefumi Kimura,

Nobuharu Tamaki

et al.

JGH Open, Journal Year: 2025, Volume and Issue: 9(4)

Published: April 1, 2025

ABSTRACT Background and Aim Noninvasive tests (NITs), such as platelet‐based indices ultrasound/MRI elastography, are widely used to assess liver fibrosis in metabolic dysfunction‐associated steatotic disease (MASLD). However, platelet counts not routinely included Japanese health check‐ups, limiting their utility large‐scale screenings. Additionally, while effective, is costly less accessible routine practice. Most existing AI‐based models incorporate these markers, restricting applicability. This study aimed develop a simple yet accurate AI model for staging using only demographic biochemical markers. Methods retrospective analyzed biopsy‐proven data from 463 MASLD patients. Patients were randomly assigned training ( N = 370, 80%) test 93, 20%) cohorts. The incorporated age, sex, BMI, diabetes, hypertension, hyperlipidemia, blood markers (AST, ALT, γ‐GTP, HbA1c, glucose, triglycerides, cholesterol). Results Support Vector Machine demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.886 detecting significant (≥ F2). AUCs advanced F3) cirrhosis (F4) 0.882 0.916, respectively. Compared FIB‐4, APRI, FAST score (0.80–0.96), SVM achieved comparable accuracy eliminating need count or elastography. Conclusion accurately assesses patients without requiring Its simplicity, cost‐effectiveness, strong performance make it well‐suited screenings clinical use.

Language: Английский

Citations

0
Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease DOI Creative Commons
Gian Paolo Caviglia, Elisabetta Casalone, Chiara Rosso

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

ABSTRACT Background and Aims MicroRNAs (miRNAs) are short non‐coding oligonucleotides involved in the post‐transcriptional regulation of gene expression. We investigated association between miRNome profile circulating extracellular vesicles (EVs) metabolic derangements, hepatic pro‐inflammatory cytokines, liver damage across histological spectrum dysfunction‐associated steatotic disease (MASLD). Methods EV miRNAs expression was determined by NGS (NextSeq550, Illumina Inc) 228 biopsy‐proven MASLD patients. In vivo studies were performed a subgroup 54 patients tracer infusion ([6,6‐ 2 H ]glucose [ 5 ]glycerol) to assess glucose lipid fluxes insulin resistance (IR) adipose tissue. Results Seven (miR‐27b‐3p, miR‐30a‐5p, miR‐122‐5p, miR‐375‐3p, miR‐103a‐3p, let‐7d‐5p, let‐7f‐5p) differentially expressed according diagnosis steatohepatitis presence significant fibrosis ( F ≥ 2), thus marking subjects with ‘at‐risk MASH’. studies, above‐reported had strongest associations metabolism: miR‐122‐5p miR‐375‐3p levels directly correlated free fatty acids (FFAs) tissue (AT)‐IR, while let‐7d‐5p let‐7f‐5p inversely lipolysis, FFAs, progressively decreased AT‐IR severity. addition, which increased increasing degrees AT‐IR. Conclusions Our results suggest an intertwined connection let‐7 family modulating derangements inflammatory pathways MASH’, paving basis for further aiming at investigating their potential therapeutic value.

Language: Английский

Citations

0
Deep Learning-Based Prediction Models for Liver-Related and Cardiovascular Events in Steatotic Liver Disease DOI

Shun‐ichi Wakabayashi,

Takefumi Kimura,

Nobuharu Tamaki

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
MetALD: clinical aspects, pathophysiology and treatment DOI Creative Commons
Jordi Gratacós‐Ginès, Sílvia Ariño, Pau Sancho‐Bru

et al.

JHEP Reports, Journal Year: 2024, Volume and Issue: 7(2), P. 101250 - 101250

Published: Nov. 2, 2024

Language: Английский

Citations

2